title: Current optimal chemotherapy for advanced urothelial cancer.
abstract: Conventional frontline cisplatin-based combination chemotherapy with gemcitabine and cisplatin, or traditional or dose-dense methotrexate, vinblastine, doxorubicin and cisplatin, yields high response rates but few durable remissions for advanced urothelial cancer. Salvage therapy is generally disappointing with few responses. A significant proportion of patients exhibit renal dysfunction, entailing carboplatin-based regimens that appear inferior to cisplatin-based regimens, which warrants a special focus In this population. The profusion of novel biologic agents offers the promise of improved outcomes. A multidisciplinary approach is necessary to make therapeutic advances.
authors: US Oncology Research & Texas Oncology PA, 501 Medical Center Blvd, Webster, TX 77598, USA. guru.sonpavde@usoncology.com
authors: Guru
authors: G
authors: Sonpavde
authors: Matthew D
authors: MD
authors: Galsky
authors: Thomas E
authors: TE
authors: Hutson
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D006801:Humans; D014571:Urologic Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000556:secondary